Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7300935 | MYOVANT SCIENCES | Thienopyrimidine compounds and use thereof |
Jan, 2025
(9 months from now) | |
US8058280 | MYOVANT SCIENCES | Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof |
Jan, 2025
(9 months from now) | |
US11795178 | MYOVANT SCIENCES | Compositions of thienopyrimidine derivatives |
Sep, 2033
(9 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9346822 | MYOVANT SCIENCES | Thienopyrimidine compounds and use thereof |
Feb, 2024
(2 months ago) | |
US11033551 | MYOVANT SCIENCES | Methods of treating uterine fibroids |
Sep, 2037
(13 years from now) | |
US11793812 | MYOVANT SCIENCES | Methods of treating endometriosis |
May, 2038
(14 years from now) |
Myfembree is owned by Myovant Sciences.
Myfembree contains Estradiol; Norethindrone Acetate; Relugolix.
Myfembree has a total of 6 drug patents out of which 1 drug patent has expired.
Expired drug patents of Myfembree are:
Myfembree was authorised for market use on 26 May, 2021.
Myfembree is available in tablet;oral dosage forms.
Myfembree can be used as management of moderate to severe pain associated with endometriosis, management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women.
Drug patent challenges can be filed against Myfembree from 18 December, 2024.
The generics of Myfembree are possible to be released after 03 May, 2038.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Dec 18, 2025 |
New Product(NP) | May 26, 2024 |
M(M-289) | Jan 27, 2026 |
New Indication(I-898) | Aug 05, 2025 |
Drugs and Companies using ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX ingredient
NCE-1 date: 18 December, 2024
Market Authorisation Date: 26 May, 2021
Treatment: Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women; Management of moderate to severe pain associated with endometriosis
Dosage: TABLET;ORAL